文献速递白血病

慢性髓性白血病的免疫机制与治疗进展

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2026-06-25

慢性髓性白血病由t(9;22)形成BCR::ABL1融合基因驱动,酪氨酸激酶抑制剂显著改善慢性期患者生存,但仍面临耐药、不耐受、白血病细胞持续存在及母细胞期进展等挑战。本综述讨论参与CML发生、进展和控制的免疫机制,并汇总当前已批准或研究中治疗方法的支持证据。

要点

  • CML由造血干细胞中t(9;22)形成的BCR::ABL1融合癌基因驱动。
  • TKI显著改善CML-CP总生存,但耐药、不耐受和白血病细胞持续存在仍是挑战。
  • 免疫调节通路和免疫监视恢复是促进无治疗缓解的潜在靶点。

核心结论

  • 靶向免疫调节通路和恢复免疫监视机制可能促进强免疫应答和无治疗缓解成功,尤其在可能需要数十年TKI治疗的儿童CML患者中。

研究设计与样本

  • 综述,讨论参与CML发生、进展和控制的免疫机制,并汇总当前已批准或研究中治疗方法的支持证据。

主要发现

  • CML由9号与22号染色体相互易位t(9;22)导致造血干细胞中BCR::ABL1融合癌基因组成性激活所定义。
  • CML主要诊断于老年人,但也可发生于儿童、青少年和年轻成人。
  • CML-CP治疗策略(包括小分子TKI开发)已大幅改善总生存和疾病复发。
  • CML治疗仍面临耐药、不耐受、白血病细胞持续存在及进展至CML-BP的风险等挑战。
  • 儿科肿瘤医生的标准化治疗遵循成人CML指南,未考虑儿科患者宿主或疾病生物学差异。

临床怎么用

  • CML-CP患者可采用小分子TKI治疗以改善总生存和疾病复发。
  • 儿童CML患者可能需数十年TKI治疗,应考虑免疫调节通路和免疫监视恢复策略以促进TFR。
  • 儿科CML治疗不应简单沿用成人指南,需考虑宿主或疾病生物学差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) is defined by the reciprocal translocation between chromosomes 9 and 22 [t(9;22)], resulting in the constitutively active BCR::ABL1 fusion oncogene in hematopoietic stem cells (HSC). CML is mostly diagnosed in older adults. However, it can also occur in children, adolescents, and young adults. Therapeutic strategies for chronic phase-CML (CML-CP) have drastically improved overall survival and disease relapse, including the development of small molecular tyrosine kinase inhibitors (TKI). However, therapeutic approaches in CML still face challenges and potential downfalls, including resistance, intolerance, persistence of leukemic cells (LCs) that risk the progression to blast phase-CML (CML-BP), and other challenges in effectiveness. Furthermore, standardized treatment by pediatric oncologists follows guidelines designed for adult CML patients and does not consider differences in host or disease biology in pediatric patients. Although some patients can achieve treatment-free remission (TFR), most patients require lifelong TKI therapy. Thus, an attractive goal in CML, particularly in children with CML, who may need several decades of TKI treatment, is to identify and target immunoregulatory pathways and restoration of immune surveillance mechanisms to promote strong immune responses and TFR success. In this review, we discuss the immunological mechanisms that contribute to the development, progression and control of CML, including supporting evidence of currently approved or investigated therapeutic approaches.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ybarra TK, Sathianathen RS, Hamidi R, et al. Immunological mechanisms and therapeutic advances in chronic myeloid leukemia. Leukemia. 2026. PMID: 42350605. doi:10.1038/s41375-026-03006-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。